The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer
Until recently, systemic therapy for gastrointestinal malignancies was restricted to relatively noncancer-specific cytotoxic chemotherapy. Over the last 15 years targeted therapies have become available, most notably bevacizumab in the case of advanced colorectal cancer. Unfortunately, there are no...
Main Authors: | Danielle Desautels, Craig Harlos, Piotr Czaykowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Journal of Carcinogenesis |
Subjects: | |
Online Access: | http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2014;volume=13;issue=1;spage=13;epage=13;aulast=Desautels |
Similar Items
-
Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data
by: Kankeu Fonkoua LA, et al.
Published: (2021-08-01) -
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer – the multinational MATEO study
by: Georg-Martin Haag, et al.
Published: (2017-07-01) -
Precision Therapy of Metastatic Colorectal Cancer with RAS Mutation
by: ZOU Jiayun, et al.
Published: (2021-08-01) -
Cervical metastasis of esophagogastric junction cancer
by: Zhiqiang Cai, et al.
Published: (2012-01-01) -
Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis
by: Stefano de Pascale, et al.
Published: (2021-02-01)